Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 160

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 4
Chunk 160
---
;

•Trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers;

•Our ability to increase penetration into our existing customer segments and to maintain and increase the effectiveness of our commercial organization;

•The size of the market for our solutions;

•The complexity of data generated by our products;

•Our ability to effectively manage product transitions and forecast customer demand, including for both existing and newly introduced products;

24

Table of Contents

•Our ability to generate sufficient revenue, to attain cash flows from operating activities in excess of our capital investment requirements and to achieve and maintain profitability;

•Our ability to consistently manufacture our products to necessary specifications in necessary quantities and at acceptable cost and performance level;

•Our ability to develop new products or new versions of existing products and enhance the capabilities of our existing products;

•Our dependency on revenue generated from the sale of our Chromium solutions;

•Doing business internationally, including in China and elsewhere in the Asia-Pacific region, and exposure to interest and foreign currency exchange rates;

•The ability of suppliers to meet our needs and the needs of our customers;

•The complexity of our operations and manufacturing our products, including in sourcing raw materials and preventing errors and defects in our solutions;

•Our limited operating history, losses since inception, fluctuations in revenue and management of growth; and

•The success of our products in achieving and sustaining scientific acceptance and generating revenue.

Risks related to our regulatory environment and taxation:

•Our products could become subject to more onerous government regulation; 

•Changes in tax laws or regulations that are applied adversely to us or our customers; and

•Ethical, legal, privacy and social concerns or governmental restrictions surrounding the use of the genomic and multiomic information and gene editing.

Risks related to our intellectual property, information technology and data security:

•Our ability to obtain, maintain and protect our intellectual property rights; and

•Our dependence on certain intellectual property rights that are licensed to us.

Risks related to litigation and our intellectual property:

•Our potential involvement in lawsuits in connection with intellectual property rights; and

•Our ability to effectively protect and enforce our intellectual property rights.

Risks related to ownership of our Class A common stock:

•The multi-class structure of our common stock; and

•The requirement of our bylaws that the State of Delaware is the exclusive forum for substantially all disputes between us and our shareholders.

General risks:

•Our ability to meet our publicly announced guidance or other expectations about our business; and

•The volatility of the market price of